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B I O P H Y S I C S
Proteasomal degradation of the intrinsically disordered 
protein tau at single-residue resolution
T. Ukmar-Godec1,2*, P. Fang3*, A. Ibáñez de Opakua1*, F. Henneberg4, A. Godec5, K.-T. Pan3, 
M.-S. Cima-Omori1, A. Chari4, E. Mandelkow6,7, H. Urlaub3,8, M. Zweckstetter1,2,9†
Intrinsically disordered proteins (IDPs) can be degraded in a ubiquitin-independent process by the 20S proteasome. 
Decline in 20S activity characterizes neurodegenerative diseases. Here, we examine 20S degradation of IDP tau, a 
protein that aggregates into insoluble deposits in Alzheimer’s disease. We show that cleavage of tau by the 20S 
proteasome is most efficient within the aggregation-prone repeat region of tau and generates both short, 
aggregation-deficient peptides and two long fragments containing residues 1 to 251 and 1 to 218. Phosphoryla-
tion of tau by the non-proline–directed Ca2+/calmodulin-dependent protein kinase II inhibits degradation 
by the 20S proteasome. Phosphorylation of tau by GSK3, a major proline-directed tau kinase, modulates tau 
degradation kinetics in a residue-specific manner. The study provides detailed insights into the degradation 
products of tau generated by the 20S proteasome, the residue specificity of degradation, single-residue degra-
dation kinetics, and their regulation by posttranslational modification.
INTRODUCTION
Intrinsically disordered proteins (IDPs) are abundant in the human 
proteome and are implicated as therapeutic targets in major human 
diseases (1). IDPs have amino acid sequences of low complexity and 
lack an ordered three-dimensional (3D) structure (1). This allows 
IDPs to dynamically bind to diverse interaction partners and thus 
influence many biological processes (1). The activity of IDPs is reg-
ulated by posttranslational modifications including phosphorylation 
and truncation (1, 2). Because of their structural instability, IDPs 
are particularly sensitive to proteolytic degradation (3–5).
Aggregation of IDPs into insoluble deposits is the hallmark of 
neurodegenerative diseases (3). Aggregates of the IDP tau are linked 
to the progression of Alzheimer’s disease (AD) and are found in other 
age-related disorders termed tauopathies (6). The longest tau isoform 
in the human central nervous system comprises 441 residues (7). The 
N-terminal ~150 residues of tau project away from the microtubule 
surface and are thus termed projection domain (8). The central part 
of the tau sequence is formed by pseudo-repeats, which bind to 
microtubules (8, 9) and are essential for pathogenic aggregation and 
folding into cross- structure in tau amyloid fibrils (10, 11). Phos-
phorylated tau accumulates during the development of AD (6, 12).
The 20S proteasome forms the proteolytic core particle of the 26S 
proteasome holoenzyme (13). In contrast to the proteasomal degra-
dation of most cellular proteins, IDPs can be degraded by the 20S 
proteasome in an ubiquitin- and adenosine triphosphate (ATP)– 
independent process without the necessity of the 19S regulatory 
particle (3–5). Soluble tau is degraded by the 20S proteasome (14, 15), 
while phosphorylation and aggregation of tau inhibit its turnover 
by the proteasome (2, 15–17). Decline of proteasomal activity and 
accumulation of tau have been linked to neurodegeneration (2, 18, 19): 
Decreased proteasomal activity results in tau accumulation, neuro-
toxicity, and cognitive dysfunction in cell and animal models of 
neurodegenerative disorders. Pharmacological activation of the 20S 
proteasome, direct administration of proteasome, or targeted pro-
teasomal degradation of tau is therefore the focus of current thera-
peutic strategies targeting tauopathies (20, 21).
Here, we study the degradation of the IDP tau by the 20S proteasome 
through a residue-specific and quantitative approach that combines 
nuclear magnetic resonance (NMR) spectroscopy and mass spec-
trometry (MS). We provide detailed insights into the identity and 
properties of the proteasomal degradation products of tau, the single- 
residue degradation kinetics, and their specific regulation by phos-
phorylation in different tau domains/by different kinases.
RESULTS
The 20S proteasome processes tau
The 20S proteasome (20S) is a barrel-shaped complex comprised by 
two stacked heptameric -rings that are sandwiched by two heptameric 
-rings (Fig. 1A) (13). The proteolytic sites, which hydrolyze the pep-
tide bonds of substrates, are located in the  subunits. IDPs thus 
traverse through the -rings to reach the active sites in the interior 
of the 20S proteasome (Fig. 1B). To study degradation of the IDP 
tau, we recombinantly prepared 20S from Thermoplasma acidophilum, 
which contains only one type of  subunit and one type of  subunit. 
This 20S particle thus has 14 identical chymotrypsin-like active sites, 
which are positioned at equal distances around the -rings (Fig. 1B). 
Electron microscopy (EM) showed intact barrel-shaped 20S com-
plexes (Fig. 1C). The 441-residue isoform of tau (hTau40; also termed 
2N4R tau; Fig. 1D) was also expressed in Escherichia coli.
Recombinant hTau40 was incubated with the 20S proteasome, 
and degradation was followed by SDS–polyacrylamide gel electro-
phoresis (PAGE) (Fig. 1E, left). After ~150 min, a clear decrease in 
1German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075 
Göttingen, Germany. 2Department of Neurology, University Medical Center Göttingen, 
University of Göttingen, Waldweg 33, 37073 Göttingen, Germany. 3Max Planck 
Institute for Biophysical Chemistry, Research group Mass Spectrometry, Am Fassberg 
11, 37077 Göttingen, Germany. 4Department for Structural Dynamics, Max-Planck 
Institute for Biophysical Chemistry, Am Fassberg 11, 37077 Göttingen, Germany. 
5Mathematical Biophysics Group, Max Planck Institute for Biophysical Chemistry, 
Am Fassberg 11, 37077 Göttingen, Germany. 6German Center for Neurodegenerative 
Diseases (DZNE), Venusberg-Campus 1, Geb. 99, 53127 Bonn, Germany. 7CAESAR 
Research Center, Ludwig-Erhard-Allee 2, 53175 Bonn, Germany. 8Bioanalytics, Institute 
for Clinical Chemistry, University Medical Center, Robert-Koch-Strasse 420, 37075 
Göttingen, Germany. 9Department for NMR-based Structural Biology, Max Planck 
Institute for Biophysical Chemistry, Am Fassberg 11, 37077 Göttingen, Germany.
*These authors contributed equally to this work.
†Corresponding author. Email: markus.zweckstetter@dzne.de
Copyright © 2020 




for the Advancement 
of Science. No claim to 
original U.S. Government 
Works. Distributed 
under a Creative 
Commons Attribution 
NonCommercial 











Ukmar-Godec et al., Sci. Adv. 2020; 6 : eaba3916     22 July 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
2 of 12
the intensity of the hTau40 band at ~60 kDa was apparent (lane 4 in 
Fig. 1E). In addition, two bands running at ~30 and 28 kDa appeared. 
Analysis after 48 hours of incubation confirmed the presence of the 
two new bands, while the full-length protein was degraded to near 
completion (lane 5 in Fig. 1E).
N-terminal cleavage intermediates
The two intermediate bands were precisely and independently 
excised from the gel, subjected to in-gel digestion using trypsin, 
which specifically cleaves at the peptide bond C terminus of lysine 
or arginine residues, and analyzed using liquid chromatography 
(LC)–MS/MS. For both bands, the MS analysis confidently identi-
fied several peptides from the N-terminal domain (Fig. 1E, right). 
No peptides were identified in the region from 127 to 210, which 
contains multiple lysine and arginine residues such that trypsin di-
gestion will produce too short sequences to be analyzed by LC-MS/MS. 
In the case of the upper band, the additional peptide RTPSLPTPPTR 
(residues 211 to 221 of hTau40) was identified (Fig. 1E, right).
We also separated the two long fragments using LC and detected 
their molecular weight by intact MS, giving masses of 25.782 and 
22.257 kDa (fig. S1). Manual matching of the determined masses to 
N-terminal sequences of hTau40 showed that the long fragment 
contains residues 1 to 251, and the short one has residues 1 to 218. 
Previous studies showed that the upper band is recognized by the 
antibody Tau-5 (14), which binds to residues in the region from 218 
to 225 (22).
Structural properties of N-terminal cleavage intermediate
To gain insight into the structural properties of the long tau frag-
ments generated during 20S degradation, we recombinantly prepared 
a tau protein comprising residues 1 to 239 of hTau40. Tau(1–239) 
contains the full epitope for the Tau-5 antibody (residues 218 to 225) 
and has a length in between the two long N-terminal fragments. 
Particle size analysis by dynamic light scattering (fig. S2A) showed 
that both hTau40 and Tau(1–239) are more compact than the average 
size values for IDPs (fig. S2B) (23). hTau40, with an experimental 
Fig. 1. Degradation of the IDP tau by the 20S proteasome. (A) Schematic representation depicting the architecture of the 20S proteasome (20S) comprising 28 subunits 
arranged in four heptameric rings (7777). (B) The proteolytic active sites of the 20S proteasome are located in its interior, thus enabling degradation of hTau40 into 
short peptides once it has entered the 20S core. (C) Negatively stained EM micrograph of the 20S proteasome. (D) Domain organization of full-length hTau40 composed 
of 441 amino acids (aa) (UniProt ID 10636-8). N1 and N2 are the two inserts in the N-terminal projection domain, P1 and P2 correspond to the two proline-rich regions, 
and R1 to R′ are five pseudo-repeats. (E) (Left) SDS-PAGE gel showing hTau40 (1) and the degradation of (2 to 5) hTau40 by the 20S proteasome over time. The samples 
were incubated at 37°C for 30 min (2), 90 min (3), and 150 min (4) and were subsequently put at 4°C for additional 48 hours (5). After 48 hours, two well-resolved bands at 
~28 and ~30 kDa (red lined box) appeared. (Right) The amino acid sequences of the upper (~30 kDa) and lower bands were identified with in-gel analysis and marked in 
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size of 5.2 nm and an expected size for its number of residues of 5.5 nm, 
is 5% more compact than expected, while Tau(1–239) is 18% more 
compact than expected with 3.3 and 4 nm as experimental and 
expected sizes, respectively. Despite the stronger compaction of 
Tau(1–239), both proteins present the typical pattern of random 
coil conformation in circular dichroism spectra (fig. S2C).
Figure S2D shows the 1H-15N heteronuclear single-quantum co-
herence (HSQC) spectrum of 15N-labeled Tau(1–239). The back-
bone cross peaks are located in the region between 7.6 and 8.6 parts 
per million (ppm), which is characteristic for IDPs. When compared 
to hTau40, chemical shift perturbation was restricted to the most 
C-terminal residues of Tau(1–239) (fig. S2E), i.e., residues where 
Tau(1–239), but not hTau40, ends. Analysis of the secondary struc-
ture propensities using the chemical shifts of carbonyl and C (fig. 
S2F) furthermore showed that both hTau40 and Tau(1–239) are 
mainly random coil, in agreement with circular dichroism spectra 
(fig. S2C).
In addition, the single-residue analysis showed that Tau(1–239) 
contains elements of transient secondary structure: residues 116 to 
119 with a tendency for helical structure and two short stretches 
(residues 150 to 152 and 225 to 230) with extended conformation. 
The same transiently structured regions were detected in hTau40 
(fig. S2F). TALOS+ also identified four regions with preference for 
extended conformation (residues 275 to 279, 306 to 310, 337 to 339, 
and 392 to 399) and one with helical content (residues 431 to 437) 
in hTau40, in agreement with previous analysis (24). The presence 
of extended conformations in the repeat region has previously been 
suggested to be responsible for the observation that the repeat re-
gion of tau, which is not present in Tau(1–239), is less compact when 
compared to a pure random coil conformation. The combined data 
thus point to a compaction of the N-terminal cleavage intermediates 
of hTau40 (fig. S2, A and B).
Tau peptides generated by the 20S proteasome
To identify short tau peptides generated by 20S, we analyzed the 
released peptides in the supernatant after incubation of hTau40 and 
20S using MS. The largest fraction of identified peptides was from 
hTau40’s pseudo-repeat region (Fig. 2, A and B). In addition, peptides 
from the C-terminal domain and the residue regions 2 to 13, 84 to 
103, and 167 to 192 were detected but with very low responses in 
MS in the supernatant (Fig. 2C). The tau peptides and their cleavage 
sites identified by MS are generally in good agreement with the pro-
teasomal cleavage sites predicted by NetChop 3.1 (Fig. 2B) (25).
The peptide with the highest ion peak area was 309VYKPVDL315 
(Fig. 2C, right). It partially overlaps with the hexapeptide sequence 
306VQIVYK311 at the beginning of pseudo-repeat R3 (Fig. 2B).
20S-generated tau peptide does not form amyloid
The 306VQIVYK311 sequence is the most hydrophobic residue stretch 
of tau, is a major driving force for pathogenic tau aggregation, and 
can form amyloid-like filaments in isolation (26). We therefore tested 
whether the 20S-generated tau peptide 309VYKPVDL315 can aggregate 
into amyloid fibrils. To this end, the 309VYKPVDL315 peptide was 
incubated with heparin at a molar ratio of 4:1.
Figure 2D shows the results from thioflavin-T (ThT) fluorescence 
measurements of 309VYKPVDL315/heparin samples at three different 
peptide concentrations during incubation at 37°C for 6 days. For all 
of the samples, the background-corrected ThT intensity was very 
low and did not increase during incubation (Fig. 2D). No increase 
in ThT intensity was detected even when the peptide was incubated 
for 6 days in the absence of heparin (fig. S3). Because ThT fluorescence 
intensity increases upon binding to amyloid fibrils, the data show 
that the 20S-generated peptide 309VYKPVDL315 is not able/has a very 
low propensity to form amyloid fibrils.
20S degradation of tau at single-residue resolution
To gain insight into the kinetics of degradation of tau by the 20S 
proteasome and define its residue specificity, we used NMR spectros-
copy. Figure 1A displays the 2D 1H-15N HSQC spectrum of 15N-labeled 
hTau40. The NMR spectrum was recorded at 5°C to attenuate the 
exchange of amide protons with solvent and thus exchange-induced 
NMR signal broadening. Comparison of the HSQC spectrum of 
hTau40 alone with the spectra recorded after 30 min and 66 hours 
(red) in the presence of 20S (hTau40:20S molar ratio of 4:1) showed 
that after 30 min, the spectrum of hTau40 was essentially unchanged 
(fig. S4), but after 66 hours, additional sharp cross peaks were present. 
Four of the newly appearing cross peaks overlapped with signals 
observed in a natural abundance 1H-15N HSQC spectrum of the 
309VYKPVDL315 peptide, i.e., the peptide with the highest ion peak 
area in MS (fig. S5). The degradation-associated cross peaks were 
not observed for a separate sample, which additionally contained 
the proteasome inhibitor oprozomib (Fig. 3A, right spectrum).
When tau is degraded by the proteasome into small peptides, the 
chemical environment of residues changes. To gain insights into the 
kinetics of 20S degradation, the intensity of IDP cross peaks at their 
location in the absence of 20S can be analyzed (27). Because a 1H-15N 
backbone correlation can be observed for every non-proline residue 
in the 2D 1H-15N HSQC, up to 397 (441 residues minus the C terminus 
and 43 prolines, and depending on signal overlap) sequence-specific 
probes for tau degradation are thus available.
The top panel in Fig. 3B displays the decrease of NMR signal 
intensities along the hTau40 sequence with increasing 20S incuba-
tion time. The fastest decrease occurred in the repeat domain. To derive 
residue-specific degradation rates, we fitted first-order decay kinetics 
via linear regression to the residue-specific intensity data. The highest 
rates occurred in repeat R3 and reached up to 0.015 hours−1 at 5°C 
(Fig. 3B, middle, and table S1). Fast degradation kinetics were also 
observed in the other pseudo-repeats, in agreement with similar se-
quence compositions. In addition, tau’s C terminus as well as resi-
dues ~220 to 250 at the end of the proline-rich region were rapidly 
affected by degradation.
Oprozomib predominantly inhibits the chymotrypsin-like activity 
of the 20S proteasome (28). Detailed analysis of the hTau40 spectra 
in the presence of both 20S and the small-molecule oprozomib 
showed that the cross peaks of residues in R2 and R3 decreased in 
intensity by up to 20% after 66 hours (Fig. 3B, bottom, and table S1). 
Thus, the 20S complex has residual proteolytic activity, which is not 
inhibited by oprozomib.
Phosphorylation of tau by CaMKII blocks 20S degradation
A large number of kinases can phosphorylate tau (29). These in-
clude proline-directed kinases [e.g., glycogen synthase kinase 3 
(GSK3) and cyclin-dependent kinase 5 (cdk5)] that phosphorylate 
proline- serine/threonine motifs, notably in the proline-rich region 
of tau, as well as non-proline–directed kinases [e.g., microtubule 
affinity-regulating kinase (MARK), protein kinase A (PKA), and 
Ca2+/calmodulin-dependent protein kinase II (CaMKII)], which 
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phosphorylates tau at several sites (30) and colocalizes with neuro-
fibrillary tangles (NFTs) in AD brains (31).
To gain insight into the influence of substrate phosphorylation 
on 20S degradation, we phosphorylated recombinant hTau40 with 
CaMKII in vitro. SDS-PAGE demonstrated an upfield shift in the 
hTau40 band, confirming successful phosphorylation (Fig. 4A). Ac-
cording to MS/MS analysis, CaMKII phosphorylates S131 and T135 in 
the projection domain, T212 and S214 in P2, S262 in R1, and S356 in 
R4 (30). 1H-15N NMR spectroscopy further showed that S214, S356, 
and S413 are fully phosphorylated in hTau40 (Fig. 4B). In addition, 
S262, S324, and S352 were found to be partially phosphorylated 
(Fig. 4B).
We then incubated CaMKII-phosphorylated hTau40 with 20S 
proteasome at 5°C. Even after 66 hours, no degradation peaks were 
observed in the 1H-15N HSQC spectrum (Fig. 4B and fig. S6). In 
addition, hTau40 cross-peak intensities remained largely unaffected 
(Fig. 4C and fig. S6). Similarly, CaMKII phosphorylation of the tau 
construct K18, which only contains the repeat domain, attenuated 
its degradation by the 20S proteasome (fig. S7). Thus, phosphorylation 
of tau by CaMKII interferes with the degradation of tau by the 20S 
proteasome.
Impact of phosphorylation by GSK3 on tau  
degradation kinetics
GSK3 is ubiquitously expressed in mammalian tissue and has been 
implicated as a major tau kinase in AD (32). In vitro modification of 
hTau40 by GSK3 results in phosphorylation of S46, T175, T181, 
S202, T205, T212, T217, T231, S235, S396, S400, and S404 (33). 
NMR confirmed complete phosphorylation of S396, S400, and S404 
(Fig. 5A). In contrast to CaMKII phosphorylation (Fig. 4), phos-
phorylation by GSK3 did not block proteasomal processing of hTau40 
[Figs. 5A (red spectrum) and 6]. Analysis of cross-peak intensities 
at increasing 20S incubation times further showed that rapid deg-
radation occurred in repeats R2 and R3 of hTau40 (Fig. 5B).
Figure 6 (A and B) compares the residue-specific degradation 
rates of unmodified hTau40 in the presence of the 20S proteasome 
(Fig. 6A, top), unmodified hTau40 in the presence of 20S and the 
inhibitor oprozomib (Fig. 6A, bottom), CaMKII-phosphorylated 
hTau40 and 20S (Fig. 6B, top), and GSK3-phosphorylated hTau40 
and 20S (Fig. 6B, bottom, and table S1). As calculated from the 
time-dependent decrease in cross-peak intensities, GSK3-phosphorylated 
hTau40 is most efficiently processed by the 20S proteasome in re-
peats R2 and R3. The phosphorylation of selected residues in tau’s 
Fig. 2. MS of tau peptides generated by the 20S proteasome. (A) Domain organization of hTau40. (B) Amino acid sequence of hTau40 depicting in color [color code as 
in (A)] the 20S-generated peptides, which were identified by LC-MS/MS. The peptides underlined with black dots were also present in the in-solution sample but with low 
intensities. The slashes depict all identified cleavage sites. Cleavage sites predicted by the NetChop server are marked by arrows. The bar on top of the VQIVYK sequence 
indicates the ability of this sequence to form amyloid-like filaments (26). (C) (Left) Histogram representation of the peak area of 20S-generated tau peptides [color code 
as in (A)] identified by in-solution analysis. Insert depicting the sequences of the identified peptides and the cleavage sites (marked with slashes). (Right) Histogram 
representing the most intense peptides in the R3 region. A.U., arbitrary units. (D) ThT fluorescence during incubation of the peptide 309VYKPVDL315. The peptide (50, 100, 
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C-terminal domain, however, blocks cleavage of peptide bonds in this 
region. In addition, the decay of NMR signals in the proline-rich 
region was strongly attenuated (Fig. 5B and fig. S4), in agreement 
with phosphorylation of T212, T217, T231, and S235 by GSK3 (33).
DISCUSSION
Within the cell, IDPs are constantly synthesized and degraded by 
the proteasome. Because they lack a globular structure, IDPs can 
directly be processed by the 20S proteasome without the need for 
previous ubiquitination and unfolding by the 26S proteasome (3–5, 34). 
In parallel, IDPs can be degraded in a ubiquitin-dependent manner 
by the 26S proteasome. Aggregates of IDPs cannot properly be de-
graded by the proteasome and are instead processed through autophagy 
(18, 19). In addition, tau aggregates might inhibit the activity of pro-
teasomes and thereby contribute to neurodegeneration (2, 17, 18). 
Detailed insights into the processing of tau and other IDPs by the 
20S proteasome may therefore be important for treating neuro-
degeneration and other human diseases (34).
Inhibition of the proteasome by small molecules results in increased 
amounts of tau in SH-SY5Y cells and rat brain (14, 35). In addition, 
the four-repeat isoform hTau43 (also termed 0NR4 tau) was shown 
to be degraded by the human 20S proteasome in vitro without pre-
vious ubiquitination (14). In agreement with the latter study, which 
Fig. 3. Kinetics of tau degradation by the 20S proteasome. (A) Superposition of 2D 1H-15N HSQC spectra of hTau40 at 5°C in the presence of the 20S proteasome after 
3 hours (black) and 66 hours (red) in the absence (left) and presence (right) of the proteasome inhibitor oprozomib. (B) (Top) Evolution of relative peak intensities, I(t)/I0, 
in 2D 1H-15N HSQC spectra of hTau40 in the presence of 20S with increasing incubation time at 5°C. I0 is the cross-peak intensity observed in the first HSQC. (Middle) 
Residue-specific rate constants of a first-order model of the 20S degradation kinetics of hTau40. Correlation coefficients for the fit to the first-order model are color-coded 
(color code bar to the right). Error bars represent SD. (Bottom) Evolution of relative peak intensities in 2D 1H-15N HSQC spectra of hTau40 in the presence of the 20S pro-
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used human 20S (14), we observed two relatively stable populations 
of long tau fragments from the N terminus when incubating hTau40 
with the 20S proteasome from T. acidophilum (Fig. 1). To determine 
the identity of the two hTau40 fragments, we performed MS analysis 
and found that the long and short fragments contain residues 1 to 
251 and 1 to 218, respectively (Fig. 1).
Proteasomes cleave their substrates to short peptides with mean 
lengths between 6 and 10 amino acids (4, 36). Longer (>50 amino 
acids) degradation intermediates are rarely detected, because the 
substrate is thought not to dissociate from the proteasome during 
the degradation process. The presence of two long truncated tau frag-
ments during 20S degradation is therefore unexpected. The more than 
200-residue-long tau fragments contain multiple, potential pro-
teasomal cleavage sites (Fig. 2B). To investigate whether the gener-
ation of these fragments is the result of specific structural properties 
of the N-terminal domain of hTau40, we characterized this domain 
at a single-residue level by NMR spectroscopy. The analysis showed 
that Tau(1–239) is more compact than hTau40 (fig. S2). We speculate 
that the more compact structure might interfere with 20S cleavage 
of the N-terminal fragments.
The short ~6- to 10-residue tau peptides generated by the 20S 
proteasome can further be cleaved by other proteases (2). In parallel, 
they might itself contain activity, which is relevant for pathological 
processes. Consistent with this hypothesis, the six-residue tau peptide 
306VQIVYK311 can form insoluble amyloid-like filaments in vitro 
(26). We therefore used MS to identify the tau peptides generated 
by 20S degradation (Fig. 2). From the large number of different 
20S-generated peptides, the tau peptide with the highest ion peak 
area was 309VYKPVDL315. Consistent with the high abundance of 
the 309VYKPVDL315 peptide generated by 20S degradation, signals 
corresponding to this peptide were identified in the NMR spectra of 
degraded tau (fig. S4). The 309VYKPVDL315 peptide lacks the first 
three amino acids of the filament-forming 306VQIVYK311 sequence 
but has four additional N-terminal residues including the two hydro-
phobic residues V313 and L315. Despite an overall high hydrophobicity, 
however, the tau peptide 309VYKPVDL315 did not aggregate into 
amyloid-like filaments in the presence of the aggregation enhancer 
heparin (Fig. 2D). Notably, all of the other 20S-generated peptides 
in the region from 308 to 320 also contain residue P312, i.e., a proline 
with known -strand–breaking property (Fig. 2C, right). Cleavage 
Fig. 4. Phosphorylation of tau by CaMKII blocks 20S degradation. (A) SDS-PAGE gel demonstrating phosphorylation of hTau40 by CaMKII in the presence of calmodulin. 
(B) (Left) Enlarged region with phosphorylated residues taken from the first 2D 1H-15N HSQC recorded at 5°C for a total duration of 3 hours on CaMKII-phosphorylated 
hTau40 in the presence of 20S. On top, the location of the phosphorylated residues is marked by short black lines in the context of the domain diagram of hTau40. (Right) 
Superposition of the first 2D 1H-15N HSQC spectrum (black; total measurement time: 3 hours) of CaMKII-phosphorylated hTau40 in the presence of 20S with the spectrum 
completed after 66 hours (red). (C) Relative peak intensities in 2D 1H-15N HSQC spectra of CaMKII-phosphorylated hTau40 in the presence of the 20S proteasome with 
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of tau by the 20S proteasome thus generates peptides that are unable 
to aggregate into amyloid-like filaments.
A wide range of assays have been developed to follow protein 
degradation. These assays often sample the degradation reaction at 
discrete time points using SDS-PAGE and antibody binding, auto-
radiography, protein staining, or Western blotting (37). In addition, 
proteasome activity can be analyzed through the measurement of 
fluorescence anisotropy of small-molecule dyes attached to substrate 
proteins. The identity of degradation products can furthermore be 
determined using MS. Here, we combined MS with NMR to (i) gain 
insight into the structural properties of the long degradation inter-
mediates of tau identified by MS and (ii) quantify degradation 
kinetics in the IDP tau with single-residue and high temporal reso-
lution. MS and NMR spectroscopy are thereby complementary, be-
cause MS enables large-scale identification of substrate fragments 
and peptides generated by proteasomal degradation, but cannot 
identify all released peptides, lacks single-residue resolution, and is 
limited in temporal resolution. NMR spectroscopy makes it possible 
to follow substrate degradation, while the reaction occurs in the test 
tube, and quantify degradation kinetics at high spatial/per-residue 
and temporal resolution. On the other hand, a high number of gen-
erated peptides and fragments complicate their identification by 
NMR especially for large IDPs, such as tau, which have many cross 
peaks. In addition, it has to be taken into account that the cleavage 
of a peptide bond can be “sensed” by residues that are several posi-
tions removed from the site of proteolysis (27). Because of the 
Fig. 5. Proteasomal degradation kinetics of GSK3-phosphorylated tau. (A) (Left) Enlarged region with phosphorylated residues taken from the first 2D 1H-15N HSQC 
recorded at 5°C for a total duration of 3 hours on GSK3-phosphorylated hTau40 in the presence of 20S. On top, the cartoon depicts the sites of phosphorylation of hTau40 
by GSK3. (Right) Superposition of the first 2D 1H-15N HSQC spectrum (black; total measurement time: 3 hours) of GSK3-phosphorylated hTau40 in the presence of 20S 
with the spectrum completed after 66 hours (red). (B) Relative peak intensities in 2D 1H-15N HSQC spectra of GSK3-phosphorylated hTau40 in the presence of the 20S 
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abovementioned aspects, we believe that the combination of MS and 
NMR will also be useful to investigate differences in the degradation 
pattern and substrate selectivity of 20S proteasomes from different 
organisms.
Using NMR spectroscopy, we found that the 20S degradation of 
many tau residues follows first-order decay kinetics (Fig. 3). The 
maximum degradation rate reached ~0.015 hours−1 at 5°C, which 
corresponds to a degradation half-time of ~46 hours. The reported 
half-life of tau in HT22 cells is 60 hours (15). The analysis further 
showed that the 20S proteasome from T. acidophilum preferentially 
cleaves tau in the pseudo-repeat region, with the fastest rates ob-
served in repeat R3 (Fig. 3). Repeat R3 is part of the cross- structure 
of heparin-induced tau fibrils (38). In addition, R3 is located in the 
core of paired helical filaments purified from the brains of patients 
Fig. 6. Phosphorylation-dependent degradation of the AD-related protein tau by the 20S proteasome. (A and B) Per-residue rate constants for degradation of tau 
by the 20S proteasome. Residue-specific rate constants of a first-order model of the 20S degradation kinetics of hTau40 at 5°C (A, top; same as in Fig. 3B), in the presence 
of the inhibitor oprozomib (A, bottom), of hTau40 phosphorylated by CaMKII (B, top), and of hTau40 phosphorylated by GSK3 (B, bottom). Correlation coefficients for 
the fit to the first-order model are color-coded (color code bars to the right). Error bars represent SD. (C) Schematic representation illustrating the phosphorylation- 
dependent degradation of the AD-related protein tau by the 20S proteasome: Wild-type tau (hTau40) is degraded by the 20S proteasome starting from the pseudo-repeat 
region and the C-terminal domain, producing short peptides (blue, pink, and orange) from those regions, followed by degradation of the N-terminal domain, which 
generates two long N-terminal fragments. Depending on the sites of phosphorylation, 20S degradation of tau is inhibited (CaMKII; top) or attenuated (GSK3; bottom). 
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with AD (10). The data suggest that the 20S proteasome preferentially 
degrades the regions of tau, which are important for pathogenic ag-
gregation.
SDS-PAGE analysis, in combination with antibody binding, was 
used to suggest that the degradation of tau by the 20S proteasome is 
bidirectional (14), supporting degradation models in which 20S 
degradation has a preference for the free NH2 or COOH terminus 
of a substrate (39). In contrast, we find that the proteasome degra-
dation of tau is most efficient in the repeat domain (followed by the 
C-terminal domain; Fig. 3). Our results are thus in agreement with 
reports showing that the 20S proteasome can initiate endoproteolytic 
cleavage at internal sites of IDPs (5). The efficient cleavage of the 
pseudo-repeat region also enables the generation of the two long 
fragments from the N terminus of tau (Fig. 1).
The strength of the quantitative, combined MS/NMR approach 
was further supported by the experiments, in which we studied the 
influence of phosphorylation of tau on its degradation by the 20S 
proteasome (Figs. 4 and 5). Tau molecules found in NFTs in the 
brains of patients with AD are hyperphosphorylated, and dysregulation 
of tau phosphorylation has been linked to neuronal toxicity (6). 
Consistent with the hypothesis that impaired proteasomal degradation 
results in tau accumulation, phosphomimetic tau variants were less 
efficiently degraded by the proteasome in autophagy-deficient mouse 
embryonic fibroblasts (16).
The quantitative NMR-based degradation analysis showed that 
phosphorylation of tau by the non-proline–directed serine/threonine 
kinase CaMKII inhibits degradation of tau by the 20S proteasome 
(Figs. 4 and 6). When the proteasome cannot degrade tau, autophagy 
becomes important, in agreement with the observation that autophagy 
is the primary route for clearing phosphorylated tau in neurons 
(16). However, using the same quantitative approach, we found that 
tau phosphorylated by GSK3, which phosphorylates Pro-Ser/Thr 
epitopes seen in NFTs in AD (32), only blocks cleavage in certain 
regions but does not interfere with tau cleavage in the pseudo-repeats 
R2 and R3 (Figs. 5 and 6). The regions of tau, which are no longer 
cleaved such as the C-terminal domain and the proline-rich domain, 
contain residues phosphorylated by GSK3 (Fig. 5). While GSK3 
does not phosphorylate residues in the repeat region, CaMKII 
phosphorylates S262, S324, S352, and S356 and blocks degradation 
by the 20S proteasome (Figs. 4 and 6). Phosphorylation of S262, S324, 
S352, and S356 therefore appears to play an important role in the 
inhibition of tau degradation by the 20S proteasome. S262, S324, 
S352, and S356 are also phosphorylated by microtubule-associated 
protein/MARKs, and their phosphorylation affects tau aggregation 
as well as microtubule binding of tau (40). Currently, the mechanism 
of impaired degradation of CaMKII-phosphorylated tau is unknown 
but could involve (i) an impaired/restricted entry through the 20S 
gate formed by the first 12 amino acids of the  subunit and (ii) a 
blocked interaction with the catalytic sites in the  subunit. Our 
study provides the basis to quantify with single-residue resolution 
the degradation of tau and other IDPs, their different isoforms, and 
posttranslationally modified variants and thus gain mechanistic in-
sight into disease-associated accumulation of IDPs.
MATERIALS AND METHODS
Preparation of tau
Unlabeled and 15N-labeled Tau protein (hTau40, UniProt ID 10636-8, 
441 residues) were expressed in E. coli strain BL21(DE3) from a pNG2 
vector (a derivative of pET-3a, Merck-Novagen, Darmstadt) in the 
presence of an antibiotic. In case of unlabeled protein, cells were grown 
in 1 to 10 liters of LB and induced with 0.5 mM IPTG (isopropyl- -
d-thiogalactopyranoside) at OD600 (optical density at 600 nm) of 
0.6 to 0.8. To obtain 15N-labeled protein, cells were grown in LB until 
an OD600 of 0.6 to 0.8 was reached, then centrifuged at low speed, 
washed with M9 salts (Na2HPO4, KH2PO4, and NaCl), and re-
suspended in minimal medium M9 supplemented with 15NH4Cl as 
the only nitrogen source and induced with 0.5 mM IPTG. After in-
duction, the bacterial cells were harvested by centrifugation, and the 
cell pellets were resuspended in lysis buffer [20 mM MES (pH 6.8), 1 mM 
EGTA, and 2 mM dithiothreitol (DTT)] complemented with protease 
inhibitor mixture, 0.2 mM MgCl2, lysozyme, and deoxyribonuclease 
(DNase) I. Subsequently, cells were disrupted with a French pressure 
cell press (in ice-cold conditions to avoid protein degradation). In 
the next step, NaCl was added to a final concentration of 500 mM 
and boiled for 20 min. Denaturated proteins were removed by 
ultracentrifugation at 4°C. The supernatant was dialyzed overnight 
at 4°C against dialysis buffer [20 mM MES (pH 6.8), 1 mM EDTA, 
2 mM DTT, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), and 
50 mM NaCl] to remove salt. The following day, the sample was filtered 
and applied onto a previously equilibrated ion-exchange chromatography 
column, and the weakly bound proteins were washed out with buffer 
A (same as the dialysis buffer). Tau protein was eluted with a linear 
gradient of 60% final concentration of buffer B [20 mM MES (pH 6.8), 
1 M NaCl, 1 mM EDTA, 2 mM DTT, and 0.1 mM PMSF]. Protein 
samples were concentrated by ultrafiltration (5 kDa Vivaspin from 
Sartorius) and purified by gel filtration chromatography. Last, the protein 
was dialyzed against 50 mM sodium phosphate (NaP) (pH 6.8).
Preparation of 20S proteasome
20S proteasomes from T. acidophilum were expressed from pRSETA 
containing the bicistronic gene including psmA and psmB. Trans-
formed BL21 cells were induced with 0.1 mM IPTG and incubated 
for 18 hours at 37°C. Harvested cells were resuspended in 3 ml of 
lysis buffer (50 mM Na2HPO4 pH 8.0, 300 mM NaCl) per 1 g of cells 
and lysed with the French press. The lysate was incubated at 65°C for 
15 min. Heat-denatured proteins were removed by centrifugation 
at 30,000g at 4°C. Polyethylenimine (0.1%, w/v) was added to the 
supernatant to precipitate contaminating nucleic acids. Precipitated 
nucleic acids were removed by centrifugation at 100,000g for 1 hour. 
The supernatant was subjected to differential precipitation with poly-
ethylene glycol 400 (PEG; number signifies the mean molecular weight 
of the PEG polymer). PEG400 was added to a concentration of 20% 
(v/v) to the supernatant under stirring at 18°C and incubated for 
30 min. Precipitated proteins were removed by centrifugation at 
30,000g for 30 min at 4°C. The supernatant was then precipitated 
by raising the concentration of PEG400 to 40% (v/v). The precipitate 
of this step contained the 20S proteasomes and was recovered by 
centrifugation at 30,000g for 30 min at 4°C and resuspended in puri-
fication buffer (0.05 M BisTris pH 6.5, 0.05 M K(OAc), 0.01 M 
Mg(OAc)2, 0.01 M -Glycerophosphate) containing 5% (w/v) sucrose, 
10 mM DTT, and 0.01% (w/v) lauryl maltose neopentyl glycol (LMNG) 
on an orbital shaker at 18°C. The resuspended material was loaded 
on 10 to 30% (w/v) sucrose gradients in purification buffer containing 
5 mM DTT, which are centrifuged at 284,000g for 16 hours at 4°C. 
Gradients were harvested in 400 l of fractions. SDS-PAGE was used 
to identify fractions containing 20S proteasomes. Selected fractions 
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After centrifugation (30,000g, 20 min), the supernatant was removed 
and the precipitate was resuspended in purification buffer containing 
5% (w/v) sucrose, 10 mM DTT, and 0.01% (w/v) LMNG. The resus-
pended material was loaded on linear 10 to 40% (w/v) sucrose gra-
dients in purification buffer containing 5 mM DTT, which are 
centrifuged at 284,000g for 18 hours at 4°C. Fractions containing 
20S proteasomes are yet again identified by SDS-PAGE, precipitated 
and concentrated by the addition of 40% PEG400, and resuspended 
in purification buffer containing 5% (w/v) sucrose and 5 mM DTT, 
yielding the final purified protein preparation at 26 mg/ml. Protein con-
centrations were determined by the Bradford assay (Bio-Rad, Munich, 
Germany) using bovine serum albumin (BSA) as a standard.
Negative-stain EM
For grid preparation, a protein stock solution (6 mg/ml) was diluted 
to 0.25 mg/ml with standard buffer without sucrose. Glutaraldehyde 
was added to the diluted protein solution to a concentration of 0.1% 
(v/v). After incubation for 2.5 min at room temperature, the reaction 
was quenched by the addition of 50 mM l-aspartate (pH 6.5). A 
continuous carbon foil was floated on the protein solution for 1 min 
at 4°C. A holey carbon copper grid was used to remove the continuous 
carbon foil from the protein solution. Excess liquid was removed 
with a tissue paper. Proteins were stained by floating the grid on a 
saturated uranyl formate solution for 1 min at 4°C. Remaining 
staining solution was removed with a tissue, and the grid was dried 
under ambient conditions. Negative-stain EM images were taken 
with a Philips CM200 microscope (160 kV). Images were acquired 
at a magnification of ×66,000. The pixel size corresponds to 3.34 Å 
per pixel. The TVIPS charge-coupled device camera was used to 
record the micrographs.
Phosphorylation of hTau40
hTau40 was phosphorylated by CaMKII (recombinant human CaMKII 
alpha protein from Abcam) and GSK3 [recombinant human GSK3 
beta protein (active) from Abcam]. The reaction was performed by 
mixing 0.2 mM hTau40 with 0.02 mg/ml kinase, 2 mM DTT, 2 mM 
ATP, 1 mM PMSF, and 5 mM MgCl2 in 40 mM Hepes (pH 7.4). In 
case of CaMKII, we additionally used 2 M calmodulin (bovine 
calmodulin, recombinant from Sigma), 1 mM CaCl2, and, in case of 
GSK3, 2 mM EGTA. The samples were incubated at 30°C overnight 
and buffer-exchanged to 50 mM NaP (pH 6.8). Protein concentrations 
were determined by the Bradford assay using BSA as a standard.
SDS-PAGE electrophoresis
For detection of hTau40 degradation products/fragments generated 
by the 20S proteasome (hTau40:20S molar ratio of 3:1), we used a 
18% separating gel [ddH2O, 30% acrylamide, 1.5 M tris (pH 8.8), 
10% SDS, 10% ammonium persulfate (APS), and tetramethylethyl-
enediamine (TEMED)] and a 4% stacking gel [ddH2O, 30% acryl-
amide, 1 M tris (pH 6.8), 10% SDS, 10% APS, and TEMED]. For 
validation of hTau40 phosphorylation, we used a 12% separating gel 
and a 4% stacking gel.
Intact MS
hTau40 was incubated with 20S proteasome for 150 min at 37°C 
and 1 day at 4°C. The resulting reaction sample was in 50 mM NaP 
(pH 6.8). The buffer was exchanged to MS compatible sample buffer 
using Amicon Ultra centrifugal filters with a molecular weight cut-
off of 3000. The filter was first washed using water. The reaction 
sample and 300 l of sample buffer [0.1% formic acid (FA)] were 
then added to the filter and centrifuged at 7500g for 30 min. After 
removing the buffer, 300 l of sample buffer was added and centrifuged 
for 30 min. The buffer exchange was then repeated one more time. Last, 
the samples were diluted to 100 ng/l for the following MS analysis.
The intact MS experiment was performed on Q Exactive HF-X2 
(Thermo Fisher Scientific) coupled to a Dionex UltiMate 3000 UHPLC 
system (Thermo Fisher Scientific) equipped with a PepSwift Monolithic 
Trap Column [200 m inside diameter (ID) × 5 mm] and a ProSwift 
RP-4H Monolithic Nano Column (100 m ID × 25 cm). The flow 
rate was set to 1 l/min. Mobile phase A and mobile phase B were 
0.1% (v/v) FA and 80% (v/v) acetonitrile (ACN), 0.08% FA, respec-
tively. The gradient started at 20% B and increased to 50% B in 
33 min and then kept B constant at 90% for 4 min, followed by 
re-equilibration of the column with 5% B. MS spectra were ac-
quired with the following settings: microscans, 1; resolution, 
120,000; mass analyzer, Orbitrap; automatic gain control (AGC) 
target, 3 × 106; injection time, 100 ms; mass range, 450 to 2000 mass/
charge ratio (m/z).
In-gel sample preparation
hTau40 samples were incubated with 20S proteasome (molar ratio 
of 3:1) for different times (30, 90, and 150 min at 37°C and, additionally, 
48 hours at 4°C). The samples were then analyzed by SDS-PAGE 
electrophoresis as described above. The two fragments (around 25 
to 30 kDa) were carefully cut from the gel and used for in-gel analysis. 
The in-gel digestion of the two bands was performed using trypsin 
(Promega) to the gels. In the next step, the extracted peptides were 
desalted by using stage tips. In the last step, the samples were dried 
(SpeedVac) and readied for further analysis.
In-solution sample preparation
hTau40 was incubated with 20S proteasome (molar ratio of 3:1) at 
37°C for 3 hours before the analysis. The samples were precipitated 
by acetone and put at −30°C overnight. Then, the samples were cen-
trifuged at 14,000g for 10 min, and the supernatant was collected 
and dried. In the next step, contaminates were removed by the sp3 
method, followed by direct injection into the mass spectrometer.
LC-MS/MS analysis
In-gel–digested peptides were analyzed using an Orbitrap Fusion 
Tribrid (Thermo Fisher Scientific) instrument. In-solution samples 
were analyzed using Orbitrap Fusion Lumos (Thermo Fisher Scientific). 
Both instruments are coupled to a Dionex UltiMate 3000 UHPLC 
system (Thermo Fisher Scientific) equipped with an in-house–packed 
C18 column (ReproSil-Pur 120 C18-AQ, 1.9 m pore size, 75 m 
inner diameter, 30 cm length, Dr. Maisch GmbH). Both Orbitrap 
Fusions (Tribrid and Lumos) were operating in data-dependent mode 
for MS2. Dried samples were resuspended in 5% ACN, 0.1% FA. 
Samples were centrifuged for 10 min at 14,000g, and the supernatants 
were transferred to new sample tubes. In both cases, the flow rate was 
set to 300 nl/min. Mobile phase A and mobile phase B were 0.1% FA 
(v/v) and 80% ACN, 0.08% FA (v/v), respectively. The gradient in 
Orbitrap Fusion Tribrid (in-gel samples) started at 10% B and in-
creased to 42% B in 43 min and then kept B constant at 90% for 6 min, 
followed by re-equilibration of the column with 5% B. MS1 spectra 
were acquired with the following settings: resolution, 120,000; mass 
analyzer, Orbitrap; mass range, 380 to 1500 m/z; injection time, 50 ms; 
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state, +2 to +7; dynamic exclusion after n time, n = 1, dynamic ex-
clusion duration = 60 s. MS2 parameters were as follows: first mass, 
120; activation type, higher-energy collisional dissociation (HCD); 
collision energy, 35; Orbitrap resolution, 30,000; maximum injection 
time, 250 ms; AGC target, 100,000. The gradient in Orbitrap Fusion 
Lumos (in-solution samples) increased to 30% B in 42 min and fur-
ther to 40% B in 4 min and then kept B constant at 90% for 6 min, 
followed by re-equilibration of the column with 5% B. MS1 spectra 
were acquired with the following settings: resolution, 120,000; mass 
analyzer, Orbitrap; mass range, 350 to 1600 m/z; injection time, 50 ms; 
AGC target, 5 × 105; S-Lens RF levels, 30; charge state, +2 to +7; dy-
namic exclusion after n time, n = 1, dynamic exclusion duration = 
30 s. MS2 parameters were as follows: first mass, 120; activation type, 
HCD; collision energy, 30; Orbitrap resolution, 15,000; maximum 
injection time, 120 ms; AGC target, 100,000.
LC-MS/MS data processing
Thermo Proteome Discoverer (2.1.0.81) was used for database search-
ing. In Proteome Discoverer, the Sequest HT, fixed value peptide 
spectrum match validator, and Precursor Ions Area Detector nodes 
were used. Parameters for database searching were as follows: the 
hTau40 protein sequence (P10636-8) was downloaded from Swiss-
Prot. Mass tolerance for precursors and fragment ions was set as ±10 
and ±20 ppm, respectively. Maximal missed cleavage was 4. Dynamic 
modifications were set as oxidation (M) and acetylation (protein 
N terminus). For in-gel samples, fixed modification was carbamido-
methylation (C). Trypsin was used as the enzyme, and its specificity 
was set as semi-specific. For in-solution sample, no enzyme was set. 
For precursor ions area detector, mass precision was 2 ppm. Only 
the peptides that were identified with high confidence were used in 
this study. For in-solution samples, the peak area of precursors was 
used for quantification of the identified peptides.
Peptide aggregation experiment
The peptide VYKPVDL was synthesized as trifluoroacetic acid salts 
by GenScript, and the stock solution (1 mM) was made in 25 mM 
Hepes (pH 7.4). To test whether the peptide can aggregate into 
amyloid fibrils, we used 50, 100, and 150 M of the peptide in 25 mM 
Hepes (pH 7.4). The stock solution of ThT (purchased from Sigma) 
was prepared in ddH2O, and for the binding assay, 50 M was used. 
When heparin (~20 kDa, Roth) was added to the sample, the molar 
ratio of the peptide to heparin was 4:1. ThT fluorescence was then 
measured with excitation at 440 nm and emission at 482 nm at 37°C 
using a multimode microplate reader (Spark 20M, TECAN).
NMR spectroscopy
2D 1H-15N HSQC and 3D spectra (HNCO and HNCA) of hTau40 
and Tau(1–239) were acquired at 5°C on a Bruker 800 MHz spec-
trometer equipped with triple-resonance 5-mm cryogenic probe. 
The protein concentration was 125 M in 50 mM NaP buffer (pH 6.8), 
5% D2O, 0.1% NaN3, and 50 M dextran sulfate sodium. Spectra were 
processed with TopSpin 3.5 (Bruker) and analyzed using Sparky.
NMR degradation experiments with 20S proteasome involving 
hTau40, phosphorylated hTau40, and hTau40 in the presence of the 
proteasome inhibitor were acquired and processed as explained above. 
2D 1H-15N HSQC spectra were recorded for 15N-labeled hTau40 and 
20S proteasome in a molar ratio of 4:1 in 50 mM NaP buffer (pH 6.8) 
and 10% D2O. The dead time between mixing hTau40 and 20S pro-
teasome and starting the first HSQC experiments was ~30 min.
To study the kinetics of the degradation of hTau40 by the 20S 
proteasome, 60-min HSQCs were measured every hour during the 
first 24 hours and then for 180-min HSQCs every 3 hours (for a total 
of 38 measurements) up to 66 hours. In case of the sample with the 
inhibitor as well as the phosphorylated samples, 180-min HSQCs 
were recorded every 3 hours for a total of 22 measurements (66 hours). 
For our control sample, we used the proteasome inhibitor oprozomib 
(ApexBio), which was incubated for 2 hours at 37°C in 250 molar 
excess before the experiment.
Peak intensities were extracted from a series of 1H-15N HSQC 
datasets at predetermined time intervals. After peak assignment 
with the software Sparky, the peak intensities were normalized with 
respect to the initial peak intensity for each residue, taking into 
account the duration of each HSQC. A residue was excluded from 
plotting and further analysis if a consecutively recorded peak inten-
sity increased to more than 115% of the relative intensity of the pre-
ceding measurement. Such an increase in peak intensity when 
compared to the preceding measurement can arise from more 
favorable relaxation properties in the generated peptides when com-
pared to full-length tau. In addition, peak overlap can potentially 
cause fluctuating intensities.
The peak intensities at all recorded times of the remaining (i.e., 
not excluded) residues were analyzed by fitting to first-order decay 
kinetics via linear regression of the data with respect to the analytic 
solution of the normalized first-order decay model. The fitted 
first-order decay reaction constants were plotted for all nonexcluded 
residues of hTau40. The statistical uncertainty in the determined 
degradation rates expressed in terms of SDs of fits was estimated as 
follows. For each sample, we randomly excluded five (in case of 
samples hTau40 + 20S in molar ratios of 4:1 and 4.5:1) or three (in 
case of samples hTau40 + 20S + inhibitor, hTau40 + CaMKII + 20S, 
and hTau40 + 20S + GSK3) intensity profiles collected at the various 
time intervals from the fitting procedure and repeated this procedure 
20 times. The selection was performed by randomly drawing five 
(three, respectively) numbers from a uniform distribution over all 
profiles measured at different time intervals, and the fitting proce-
dure was carried out on each of these subsamples and each amino acid 
residue. From the 21 fits per residue obtained this way (20 “under-
sampled” plus 1 fit based on all measured profiles), we calculated the 
sample SD and depicted it as error bars. The plots depicting degrada-
tion rates were plotted as the full-data fit (declared here as the mean 
estimated value) plus/minus the SD. In addition, we determined the 
Pearson correlation coefficients  for all respective fits, which are 
encoded in the color. Fits with an incorrect sign of  (i.e., implying 
an incorrect/unphysical trend) were excluded from the plot.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/30/eaba3916/DC1
View/request a protocol for this paper from Bio-protocol.
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